semaglutide for liver disease Landmark Study Finds Effectively Treats Serious : ScienceAlert New analysis of trial of

(An active ingredient is what makes a drug work.) It belongs to a class of drugs called glucagon-like peptide-1 receptor agonists

In April 2024, the pharma company reported the topline results of a trial that found that people with obesity and sleep apnea who took tirzepatide (brand name Zepbound) for a year lost an average of 20% of their body weight and experienced a far larger reduction in apnea-related events at night than people taking a placebo

Antioxidants protect cells from reactive oxygen species such as free radicals and peroxides

[14] More recently, the SELECT trial showed that semaglutide 2.4 mg reduced cardiovascular events by 20% in patients with established cardiovascular disease and overweight/obesity without diabetes